Pierson Surgical © All Rights Reserved. Privacy Policy | Terms of Use
Surgical Products
Beating-Heart Self-Expanding Pulmonic Valve – designed for use Off Pump
· Large-diameter trocar implantation; no bypass necessary
· Low Profile
· No Distal or Proximal Suture Lines
· No Coronary Compression
· Enables Primary or Secondary Repair of Tetralogy of Fallot
· A full range of sizes from 15 - 31 mm is available to match patient morphology
· No reported structural failures or stent fracture over 7 years
· 7 years’ experience - longest of any transapical heart valve
No-React® Injectable Pulmonic Valve
Patients born with Tetralogy of Fallot or other forms of pulmonary valve malfunction will require early surgical intervention. Later in life they will need pulmonary valve replacement with either a homograft or a tissue valve. However standard glutaraldehyde treated tissue has limited durability and is prone to infection, rejection, adhesions, calcification and thrombosis, requiring repeat operations in the future.
The No-React® Injectable Pulmonic Valve (NRIP) is the only device on the market that offers the combination of a highly durable, infection, calcification and dilatation resistant tissue valve with an implantation system that avoids the risks associated with repeated cardiopulmonary bypass (CPB) supported operations.
The potential benefits of the NRIP for Secondary Repair include :
- Faster recovery and a lower risk of post-operative morbidity
- Shorter operating times
- Cost savings – theatre costs are lower, no CPB consumables,post-operative care is reduced (shorter duration of ventilation, intensive care and overall hospital stay; fewer blood products; fewer resources to treat comorbidity).
- Fewer operations required in the future for the patient owing to greater longevity of the No-React® NRIP device than standard glutaraldehyde treated devices
“The new,self-expanding,catheter-based pulmonary valve [The No-React® Injectable Pulmonic] is easy to implant via an Antegrade (RVOT,RV)or retrograde approach(PA)even in dilated RV outflow tracts. The procedure can be done without CPB under echocardiographic guidance.”
Schlensak et al
“A New Concept in the Surgical Treatment of ToF Using An Injectable Pulmonic Valve for Total Primary Repair. “
Professor Piero Abbruzzese et al , Regina Margherita Paediatric Hospital, Turin
Infants and children under the age of 5 needing conduits for ToF repair may require a further 2 to 4 operations before adulthood. Using an injectable biological oversized valve squeezed to a diameter which is appropriate for age and chest dimensions promises longer freedom from reoperation.
PRIMARY REPAIR
SECONDARY REPAIR